[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University College Hospital, Ibadan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100421751","phase-2-microrna-profiles-in-triple-negative-breast-cancer-100421751",false,"NCT04771871","MicroRNA Profiles in Triple Negative Breast Cancer","Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patients Receiving Standard Chemotherapy","TARMAC","Inclusion Criteria:\n\n1. Women ages of 18 to 70 years old\n2. Women who give informed consent for the study\n3. Biopsy-accessible breast tumor of significant size for core needle biopsy\u002Fultrasound measurable (≥ 2cm)\n4. Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)\n5. Clinical stages IIA -IIIC (AJCC 2009)\n6. Chemotherapy-naïve patients (for this malignancy)\n7. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n8. Non-pregnant and not nursing. Women of childbearing potential must take the pregnancy test and must commit to receive Leuteinizing Hormone Realising Hormone (LHRH) agonist Zoladex (goserelin) for two years starting from the commencement of the study medications\n9. Required Initial Laboratory Data. Adequate hematologic, renal and hepatic function, as defined by each of the following:\n\n1\\. Granulocyte ≥ 1,500\u002FμL 2. Platelet count ≥ 100,000\u002FμL 3. Absolute neutrophil count (ANC) ≥ l500\u002FμL 4. Hemoglobin ≥ 10g\u002FdL 5. Bilirubin ≤ 1.5 x upper limit of normal 6. SGOT and SGPT \\\u003C 2.5 x upper limit of normal 7. Creatinine within institutional normal limits or glomerular filtration rate ≥ 30 mL\u002Fmin\u002F1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (CKD EPI) equation (see http:\u002F\u002Fmdrd.com\u002F for calculator) 10. Echocardiogram (ECHO): Baseline left ventricular ejection fraction of ≥ 55%\n\nExclusion Criteria:\n\n1. Pregnant or lactating women. Women of childbearing potential not using a reliable and appropriate contraceptive method. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.\n2. Patients with distant metastasis (brain and\u002For visceral metastasis)\n3. Serious, uncontrolled, concurrent infection(s).\n4. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS)\n5. Participation in any investigational drug study within 4 weeks preceding the start of study treatment\n6. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled Diabetes mellitus, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.","FEMALE","18 Years","70 Years",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups. There is no targeted therapy unlike other types of breast cancer such as hormone positive and Human Epidermal Growth factor 2 (HER2) positive subtypes. Chemotherapy is therefore the main choice of systemic treatment with rapid development of resistance in most cases. At present, there is no blood test to monitor treatment response and disease relapse. This one-stage phase II study with a single arm design will determine the response rate of standard chemotherapy using Epirubicin (60mg\u002Fm2), Cyclophosphamide (600mg\u002Fm2) , Paclitaxel (120mg\u002Fm2) and Carboplatin (6AUC) in TNBC patients. We will measure the blood level of microRNA molecules and circulating tumor DNA during and after treatment to test if changes can be used to indicate drug failure in these patients. Disease status and tumor response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines while toxicity will be assessed using CTCAE v5). The trial will be conducted as per the International Council on Harmonisation Good Clinical Practice (ICH GCP) Guidelines E6 (R1) and other applicable guidelines",[28],"Triple Negative Breast Cancer",[30,31,32,33],"Breast cancer","neoadjuvant treatment","microRNA","circulating tumor cells","RECRUITING","2026-04-30",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":38},"2021-11-29",{"date":42,"type":22},"2030-08",{"name":44,"class":45},"University College Hospital, Ibadan","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100511247","the-ibadan-acute-and-chronic-heart-failure-project-100511247","NCT05936957","The Ibadan Acute and Chronic Heart Failure Project","Inclusion Criteria:\n\nAll cases of heart failure\n\nExclusion Criteria:\n\nNo consent to participate","ALL","100 Years",{"count":56,"type":22},2000,"5 Years","OBSERVATIONAL","Contemporary studies from South Africa and Nigeria have built on historical reports to demonstrate that the etiology and indeed case profile of acute HF (i.e. more women and younger individuals affected in the prime of their life) is different from high-income countries. As such, HF is now responsible for 7-10% of medical admissions in the region.\n\nThese are entirely based on studies on acute HF and few on chronic HF. The nexus between endemic infections such as tuberculosis (TB) and HIV\u002FAIDS and other non-communicable or non-infectious risk factors and HF in Africa is scarcely documented.\n\nThis study will assess the long-term outcomes, risk factors, clinical phenotypes, and genomics of HF in Ibadan, Nigeria, estimate catastrophic healthcare cost associated with CHF and how it affects evidence-based care; understand cultural and social conceptions of HF in the city and by extension in Nigeria.\n\nData from each subject shall be obtained using a uniform and standardized case report forms (CRF). A detailed clinical documentation on cases of HF will be undertaken.\n\nAll variables will be summarized using appropriate descriptive statistics. Means and proportions will be estimated with two-tailed 95% confidence intervals. Specified patients' outcomes will also be summarized using proportions. Factors associated wit patient outcomes will be investigated using multivariable logistic regression models. Crude and adjusted Odds Ratio (OR) with 95% confidence intervals (CI) will be estimated.\n\nThe primary event outcome of the study will be mortality by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in admission).",[61],"Heart Failure",[63],"Heart failure, Cardiac Failure","2023-06-29",{"date":66,"type":38},"2023-07-10",{"date":68,"type":38},"2015-01-01",{"date":70,"type":22},"2030-12-31",{"name":44,"class":45},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":53,"minAge":81,"maxAge":54,"enrollmentInfo":82,"targetDuration":84,"studyType":58,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100511186","nigeria-atrial-fibrillation-registry-100511186","NCT05936164","Nigeria Atrial Fibrillation Registry","The Nigeria National Registry of Atrial Fibrillation","NigAfibReg","Inclusion Criteria:\n\nAll cases of confirmed atrial fibrillation\n\nExclusion Criteria:\n\nRefusal of consent","15 Years",{"count":83,"type":22},4000,"1 Year","Atrial fibrillation is the most common sustained cardiac arrhythmia (rhythm abnormality) encountered in clinical practice. It contributes significantly to the risk of cardiac symptoms, hospital admissions, cardiovascular related morbidity and mortality and increased healthcare cost.\n\nAF has significant impact on healthcare cost. The major drivers of the cost are hospitalisations, stroke and loss of productivity. Globally AF accounts for less than 1% of all deaths. However, because it co-exists with other conditions, it contributes to worse prognosis compared to persons who do not have AF. New onset AF in HF patients may be associated with particularly poor prognosis.\n\nMost of the published data and current knowledge on AF epidemiology are based on studies in Europe and North America. The information obtainable from previous studies in sub-Saharan Africa is limited. Many of the studies were retrospective. There is also paucity of information on burden of AF (both in hospital and community), clinical profile and outcome of AF in Nigeria in particular and Africa in general.\n\nThe primary objective of this study is to determine the clinical characteristics, outcome as well as cost genetic features of AF in Nigeria.\n\nThe project will provide information on: i. Hospital and community burden of AF in Nigeria; ii. Clinical features, mode of presentation and risk factors for AF; iii. Provide data on AF related outcomes as well as prognostic factors.",[87],"Atrial Fibrillation",[89],"Atrial fibrillation, arrhythmias, heart failure","NOT_YET_RECRUITING",{"date":92,"type":38},"2023-07-07",{"date":94,"type":22},"2023-10-01",{"date":96,"type":22},"2028-12-31",{"name":44,"class":45},""]